Identification

Name
Lacidipine
Accession Number
DB09236
Type
Small Molecule
Groups
Approved, Investigational
Description

Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia [1]. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure. Compared to other dihydropyridine calcium antagonists, lacidipine exhibits a greater antioxidant activity which may confer potentially beneficial antiatherosclerotic effects [4]. Lacidipine is a highly lipophilic molecule that interacts with the biological membranes. Through radiotracer analysis, it was determined that lacidipine displays a high membrane partition coefficient leading to accumulation of the drug in the membrane and slow rate of membrane washout [3]. When visualized by small-angle X-ray diffraction with angstrom resolution to examine its location within the membranes, lacidipine was found deep within the membrane's hydrocarbon core [3]. These results may explain the long clinical half-life of lacidipine [3].

In randomised, well-controlled trials, administration of daily single-dose lacidipine ranging from 2-6 mg demonstrated comparable antihypertensive efficacy similar to that of other long-acting dihydropyridine calcium antagonists, thiazide diuretics, atenolol (a beta-blocker) and enalapril (an ACE inhibitor) [1]. It is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Caldine (Boehringer Ingelheim) / Lacimen (GlaxoSmithKline) / Lacipil (GSK) / Motens (Boehringer Ingelheim)
Categories
UNII
260080034N
CAS number
103890-78-4
Weight
Average: 455.551
Monoisotopic: 455.230787787
Chemical Formula
C26H33NO6
InChI Key
GKQPCPXONLDCMU-CCEZHUSRSA-N
InChI
InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
IUPAC Name
3,5-diethyl 4-{2-[(1E)-3-(tert-butoxy)-3-oxoprop-1-en-1-yl]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC

Pharmacology

Indication

Indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including β-adrenoceptor antagonists, diuretics, and ACE-inhibitors [6].

Structured Indications
Not Available
Pharmacodynamics

acidipine is a specific and potent calcium antagonist with a predominant selectivity for calcium channels in the vascular smooth muscle. Its main action is to dilate predominantly peripheral and coronary arteries, reducing peripheral vascular resistance and lowering blood pressure [6].

Following the oral administration of 4 mg lacidipine to volunteer subjects, a minimal prolongation of QTc interval has been observed (mean QTcF increase between 3.44 and 9.60 ms in young and elderly volunteers) [6].

Mechanism of action

By blocking the voltage-dependent L-type calcium channels, it prevents the transmembrane calcium influx [2]. Normally, calcium ions serve as intracellular messengers or activators in exictable cells including vascular smooth muscles. The influx of calcium ultimately causes the excitation and depolarization of the tissues. Lacidipine inhibits the contractile function in the vascular smooth muscle and reduce blood pressure. Due to its high membrane partition coefficient, some studies suggest that lacidipine may reach the receptor via a two-step process; it first binds and accumulates in the membrane lipid bilayer and then diffuses within the membrane to the calcium channel receptor [5]. It is proposed that lacidipine preferentially blocks the inactivated state of the calcium channel [5].

Through its antioxidant properties shared amongst other dihydropyridine calcium channel blockers, lacidipine demonstrates an additional clinical benefit. Its antiatherosclerotic effects are mediated by suppressing the formation of reactive oxygen species (ROS) and subsequent inflammatory actions by chemokines, cytokines and adhesion molecules, thus reducing atherosclerotic lesion formation [4]. Lacidipine may also suppress cell proliferation and migration in smooth muscle cells and suppress the expression of matrix metalloproteinases, which affects the stability of atheromatous plaques [4].

TargetActionsOrganism
AVoltage dependent L type calcium channel
antagonist
Human
Absorption

Since it is a highly lipophilic compound, lacidpine is rapidly absorbed from the gastrointestinal tract following oral administration with the peak plasma concentrations reached between 30 and 150 minutes of dosing [6]. The peak plasma concentrations display large interindividual variability, with the values ranging from 1.6 to 5.7 μg/L following single-dose oral administration of lacidipine 4mg in healthy young volunteers [2].

Absolute bioavailability is less than 10% due to extensive first-pass metabolism in the liver [6].

Volume of distribution
Not Available
Protein binding

Lacidipine is highly protein-bound (more than 95%) to predominantly albumin and to a lesser extent, alpha-1-glycoprotein [6].

Metabolism

Lacidipine undergoes complete CYP3A4-mediated hepatic metabolism, with no parent drug detected in the urine or faeces. The 2 main metabolites have no pharmacological activity [2].

Route of elimination

Approximately 70% of the administered dose is eliminated as metabolites in the faeces and the remainder as metabolites in the urine [6].

Half life

The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [6].

Clearance
Not Available
Toxicity

There have been no recorded cases of lacidipine tablets overdosage. Some of the symptoms of overdose include prolonged peripheral vasodilation associated with hypotension and tachycardia. Bradycardia or prolonged AV conduction could theoretically occur. As there is no known antidote for lacidipine, the use of standard general measures for monitoring cardiac function and appropriate supportive and therapeutic measures is recommended [6].

Oral LD50 in mouse, rabbit and rat are 300mg/kg, 3200mg/kg and 980mg/kg, respectively [MSDS].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of Lacidipine can be decreased when it is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe serum concentration of Lacidipine can be decreased when it is combined with 19-norandrostenedione.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Lacidipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Lacidipine.Vet Approved
5-androstenedioneThe serum concentration of Lacidipine can be decreased when it is combined with 5-androstenedione.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Lacidipine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AdrenaloneAdrenalone may increase the hypotensive activities of Lacidipine.Experimental
AlclometasoneThe serum concentration of Lacidipine can be decreased when it is combined with Alclometasone.Approved
AldesleukinAldesleukin may increase the hypotensive activities of Lacidipine.Approved
AldosteroneThe serum concentration of Lacidipine can be decreased when it is combined with Aldosterone.Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Lacidipine.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
AmbrisentanLacidipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideThe serum concentration of Lacidipine can be decreased when it is combined with Amcinonide.Approved
AmifostineLacidipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hypotensive activities of Lacidipine.Approved
AmiodaroneThe serum concentration of Lacidipine can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Lacidipine.Approved
AmobarbitalThe metabolism of Lacidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Lacidipine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Lacidipine.Approved, Illicit, Investigational
Amphotericin BAmphotericin B may increase the hypotensive activities of Lacidipine.Approved, Investigational
Amyl NitriteAmyl Nitrite may increase the hypotensive activities of Lacidipine.Approved
AndrostenedioneThe serum concentration of Lacidipine can be decreased when it is combined with Androstenedione.Experimental, Illicit
AnecortaveThe serum concentration of Lacidipine can be decreased when it is combined with Anecortave.Investigational
anecortave acetateThe serum concentration of Lacidipine can be decreased when it is combined with anecortave acetate.Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Lacidipine.Approved, Investigational
ApalutamideThe serum concentration of Lacidipine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineApomorphine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ApraclonidineApraclonidine may increase the hypotensive activities of Lacidipine.Approved
AprepitantThe serum concentration of Lacidipine can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the hypotensive activities of Lacidipine.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Lacidipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Lacidipine.Investigational
Arsenic trioxideArsenic trioxide may increase the hypotensive activities of Lacidipine.Approved, Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Lacidipine.Approved
AtamestaneThe serum concentration of Lacidipine can be decreased when it is combined with Atamestane.Investigational
AtazanavirThe serum concentration of Lacidipine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Lacidipine.Approved
AtomoxetineThe metabolism of Lacidipine can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Lacidipine.Approved
AZ-002AZ-002 may increase the hypotensive activities of Lacidipine.Investigational
Azilsartan medoxomilAzilsartan medoxomil may increase the hypotensive activities of Lacidipine.Approved, Investigational
BaclofenBaclofen may increase the hypotensive activities of Lacidipine.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Lacidipine.Experimental
BambuterolBambuterol may increase the hypotensive activities of Lacidipine.Approved, Investigational
BamethanBamethan may increase the hypotensive activities of Lacidipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Lacidipine.Experimental
BarbitalThe metabolism of Lacidipine can be increased when combined with Barbital.Illicit
BarnidipineLacidipine may increase the antihypertensive activities of Barnidipine.Approved
Beclomethasone dipropionateThe serum concentration of Lacidipine can be decreased when it is combined with Beclomethasone dipropionate.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Lacidipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Lacidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Lacidipine.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Lacidipine.Approved, Investigational
BepridilBepridil may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
BetamethasoneThe serum concentration of Lacidipine can be decreased when it is combined with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Lacidipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Lacidipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Lacidipine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Lacidipine.Approved
BitolterolBitolterol may increase the hypotensive activities of Lacidipine.Withdrawn
BoceprevirThe serum concentration of Lacidipine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibBortezomib may increase the hypotensive activities of Lacidipine.Approved, Investigational
BosentanThe serum concentration of Lacidipine can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Lacidipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Lacidipine.Experimental
BretyliumBretylium may increase the hypotensive activities of Lacidipine.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Lacidipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Lacidipine.Experimental
BromocriptineBromocriptine may increase the hypotensive activities of Lacidipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Lacidipine.Investigational
BudesonideThe serum concentration of Lacidipine can be decreased when it is combined with Budesonide.Approved
BufuralolBufuralol may increase the hypotensive activities of Lacidipine.Experimental, Investigational
BumetanideBumetanide may increase the hypotensive activities of Lacidipine.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Lacidipine.Investigational
BupivacaineBupivacaine may increase the hypotensive activities of Lacidipine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Lacidipine.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Lacidipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Lacidipine.Approved
ButyrylthiocholineButyrylthiocholine may increase the hypotensive activities of Lacidipine.Experimental
CadralazineCadralazine may increase the hypotensive activities of Lacidipine.Experimental
CafedrineLacidipine may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Lacidipine.Approved
CandesartanLacidipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Lacidipine.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Lacidipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Lacidipine.Experimental
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Lacidipine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Lacidipine.Approved
CarbacholCarbachol may increase the hypotensive activities of Lacidipine.Approved
CarbamazepineThe serum concentration of Lacidipine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinCarbetocin may increase the hypotensive activities of Lacidipine.Approved, Investigational
CarbuterolCarbuterol may increase the hypotensive activities of Lacidipine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Lacidipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Lacidipine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Lacidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Lacidipine.Approved
CeliprololCeliprolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
CeritinibThe serum concentration of Lacidipine can be increased when it is combined with Ceritinib.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Lacidipine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Lacidipine.Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Lacidipine.Approved
CholineCholine may increase the hypotensive activities of Lacidipine.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the hypotensive activities of Lacidipine.Approved
Choline salicylateCholine salicylate may increase the hypotensive activities of Lacidipine.Approved, Nutraceutical
CiclesonideThe serum concentration of Lacidipine can be decreased when it is combined with Ciclesonide.Approved, Investigational
CicletanineLacidipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Lacidipine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Lacidipine.Approved
CilnidipineCilnidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
CimetidineThe serum concentration of Lacidipine can be increased when it is combined with Cimetidine.Approved, Investigational
CiticolineCiticoline may increase the hypotensive activities of Lacidipine.Approved, Investigational
ClarithromycinThe serum concentration of Lacidipine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Lacidipine can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolClenbuterol may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
ClevidipineClevidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ClobetasolThe serum concentration of Lacidipine can be decreased when it is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe serum concentration of Lacidipine can be decreased when it is combined with Clobetasol propionate.Approved
ClobetasoneThe serum concentration of Lacidipine can be decreased when it is combined with Clobetasone.Approved
ClocortoloneThe serum concentration of Lacidipine can be decreased when it is combined with Clocortolone.Approved
ClofarabineClofarabine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ClomipramineClomipramine may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Lacidipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lacidipine.Approved
CloranololLacidipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Lacidipine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the hypotensive activities of Lacidipine.Approved
CobicistatThe serum concentration of Lacidipine can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Lacidipine.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Lacidipine.Investigational
Cortexolone 17α-propionateThe serum concentration of Lacidipine can be decreased when it is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe serum concentration of Lacidipine can be decreased when it is combined with Corticosterone.Experimental
Cortisone acetateThe serum concentration of Lacidipine can be decreased when it is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe metabolism of Lacidipine can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Lacidipine.Approved
CyclopenthiazideLacidipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Lacidipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Lacidipine.Approved
DabrafenibThe serum concentration of Lacidipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dantrolene.Approved, Investigational
DapagliflozinDapagliflozin may increase the hypotensive activities of Lacidipine.Approved
DarunavirThe serum concentration of Lacidipine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Lacidipine can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolDeanol may increase the hypotensive activities of Lacidipine.Experimental
DebrisoquinDebrisoquin may increase the hypotensive activities of Lacidipine.Approved, Investigational
DeferasiroxThe serum concentration of Lacidipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Lacidipine can be decreased when it is combined with Deflazacort.Approved, Investigational
DelaprilLacidipine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Lacidipine can be decreased when combined with Delavirdine.Approved
DeoxyepinephrineDeoxyepinephrine may increase the hypotensive activities of Lacidipine.Experimental
DeserpidineLacidipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneDesflurane may increase the hypotensive activities of Lacidipine.Approved
DesonideThe serum concentration of Lacidipine can be decreased when it is combined with Desonide.Approved, Investigational
DesoximetasoneThe serum concentration of Lacidipine can be decreased when it is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe serum concentration of Lacidipine can be decreased when it is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe serum concentration of Lacidipine can be decreased when it is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe serum concentration of Lacidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Lacidipine can be decreased when it is combined with Dexamethasone isonicotinate.Vet Approved
DexmedetomidineDexmedetomidine may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Lacidipine.Approved
DichloroisoproterenolDichloroisoproterenol may increase the hypotensive activities of Lacidipine.Investigational
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Lacidipine.Vet Approved
DiclofenamideDiclofenamide may increase the hypotensive activities of Lacidipine.Approved, Investigational
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Lacidipine.Investigational
DiflorasoneThe serum concentration of Lacidipine can be decreased when it is combined with Diflorasone.Approved
DifluocortoloneThe serum concentration of Lacidipine can be decreased when it is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Lacidipine can be decreased when it is combined with Difluprednate.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Lacidipine.Approved, Investigational
DihydroergotamineThe metabolism of Lacidipine can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Lacidipine.Approved, Investigational
DimetofrineDimetofrine may increase the hypotensive activities of Lacidipine.Experimental
DinutuximabDinutuximab may increase the hypotensive activities of Lacidipine.Approved, Investigational
DipivefrinDipivefrin may increase the hypotensive activities of Lacidipine.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Lacidipine.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Lacidipine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Lacidipine.Approved
DoxycyclineThe metabolism of Lacidipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Lacidipine can be decreased when combined with Dronedarone.Approved
DroxidopaDroxidopa may increase the hypotensive activities of Lacidipine.Approved, Investigational
DuloxetineLacidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Lacidipine.Approved
EdivoxetineEdivoxetine may increase the hypotensive activities of Lacidipine.Investigational
EfavirenzThe serum concentration of Lacidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Lacidipine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
EmpagliflozinEmpagliflozin may increase the hypotensive activities of Lacidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Lacidipine.Approved
EndralazineEndralazine may increase the hypotensive activities of Lacidipine.Experimental
EnzalutamideThe serum concentration of Lacidipine can be decreased when it is combined with Enzalutamide.Approved
EpanololLacidipine may increase the hypotensive activities of Epanolol.Experimental
EpinephrineEpinephrine may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
EplerenoneEplerenone may increase the hypotensive activities of Lacidipine.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Lacidipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Lacidipine.Approved
EquileninThe serum concentration of Lacidipine can be decreased when it is combined with Equilenin.Experimental
EquilinThe serum concentration of Lacidipine can be decreased when it is combined with Equilin.Approved
ErythromycinThe metabolism of Lacidipine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsmololEsmolol may increase the hypotensive activities of Lacidipine.Approved
EstroneThe serum concentration of Lacidipine can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Lacidipine can be decreased when it is combined with Estrone sulfate.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Lacidipine.Approved, Investigational
EthanolamineEthanolamine may increase the hypotensive activities of Lacidipine.Experimental
EtilefrineEtilefrine may increase the hypotensive activities of Lacidipine.Withdrawn
FelodipineFelodipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Lacidipine.Approved
FenoterolFenoterol may increase the hypotensive activities of Lacidipine.Approved, Investigational
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Lacidipine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Lacidipine.Experimental
FimasartanFimasartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
FluasteroneThe serum concentration of Lacidipine can be decreased when it is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Lacidipine can be decreased when combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Lacidipine.Approved, Investigational
FludrocortisoneThe serum concentration of Lacidipine can be decreased when it is combined with Fludrocortisone.Approved, Investigational
FlumethasoneThe serum concentration of Lacidipine can be decreased when it is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe serum concentration of Lacidipine can be decreased when it is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Lacidipine can be decreased when it is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Lacidipine can be decreased when it is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe serum concentration of Lacidipine can be decreased when it is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe serum concentration of Lacidipine can be decreased when it is combined with Fluorometholone.Approved, Investigational
FluprednideneThe serum concentration of Lacidipine can be decreased when it is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe serum concentration of Lacidipine can be decreased when it is combined with Fluprednisolone.Approved
FlurandrenolideThe serum concentration of Lacidipine can be decreased when it is combined with Flurandrenolide.Approved
Fluticasone furoateThe serum concentration of Lacidipine can be decreased when it is combined with Fluticasone furoate.Approved
Fluticasone propionateThe serum concentration of Lacidipine can be decreased when it is combined with Fluticasone propionate.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Lacidipine.Experimental
FluvoxamineThe metabolism of Lacidipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Lacidipine can be decreased when it is combined with Formestane.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypotensive activities of Lacidipine.Approved, Investigational
FosamprenavirThe metabolism of Lacidipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lacidipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Lacidipine.Approved
FosphenytoinThe serum concentration of Lacidipine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Lacidipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Lacidipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Lacidipine.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Lacidipine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Lacidipine.Approved
GuanazodineLacidipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Lacidipine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Lacidipine.Approved, Investigational
GuanoclorLacidipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLacidipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLacidipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Lacidipine.Experimental
HalcinonideThe serum concentration of Lacidipine can be decreased when it is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Lacidipine.Approved, Withdrawn
HalothaneHalothane may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Lacidipine.Experimental
HE3286The serum concentration of Lacidipine can be decreased when it is combined with HE3286.Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Lacidipine.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Lacidipine.Approved, Investigational
HexobarbitalThe metabolism of Lacidipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Lacidipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Lacidipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
HydrocortisoneThe serum concentration of Lacidipine can be decreased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Lacidipine.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the hypotensive activities of Lacidipine.Investigational
IbopamineIbopamine may increase the hypotensive activities of Lacidipine.Experimental
IdelalisibThe serum concentration of Lacidipine can be increased when it is combined with Idelalisib.Approved
IdrocilamideIdrocilamide may increase the hypotensive activities of Lacidipine.Experimental
IloprostIloprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
ImatinibThe metabolism of Lacidipine can be decreased when combined with Imatinib.Approved
ImidaprilImidapril may increase the hypotensive activities of Lacidipine.Investigational
ImipramineImipramine may increase the hypotensive activities of Lacidipine.Approved
IndapamideIndapamide may increase the hypotensive activities of Lacidipine.Approved
IndenololIndenolol may increase the hypotensive activities of Lacidipine.Withdrawn
IndinavirThe serum concentration of Lacidipine can be increased when it is combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Lacidipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Lacidipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Lacidipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
IsavuconazoleThe serum concentration of Lacidipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Lacidipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Lacidipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Lacidipine.Approved
IsofluraneIsoflurane may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypotensive activities of Lacidipine.Approved, Investigational
Isosorbide DinitrateIsosorbide Dinitrate may increase the hypotensive activities of Lacidipine.Approved, Investigational
Isosorbide MononitrateIsosorbide Mononitrate may increase the hypotensive activities of Lacidipine.Approved
IsoxsuprineIsoxsuprine may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
IstaroximeThe serum concentration of Lacidipine can be decreased when it is combined with Istaroxime.Investigational
ItraconazoleThe serum concentration of Lacidipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Lacidipine can be increased when it is combined with Ivacaftor.Approved
KetanserinKetanserin may increase the hypotensive activities of Lacidipine.Investigational
KetoconazoleThe serum concentration of Lacidipine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LevobunololLevobunolol may increase the hypotensive activities of Lacidipine.Approved
LevobupivacaineLevobupivacaine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LevodopaLevodopa may increase the hypotensive activities of Lacidipine.Approved
LevonordefrinLevonordefrin may increase the hypotensive activities of Lacidipine.Approved
LevosimendanLevosimendan may increase the hypotensive activities of Lacidipine.Approved, Investigational
LinsidomineLacidipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Lacidipine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LopinavirThe serum concentration of Lacidipine can be increased when it is combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Lacidipine can be increased when it is combined with Lorpiprazole.Approved
LosartanLosartan may increase the hypotensive activities of Lacidipine.Approved
LoteprednolThe serum concentration of Lacidipine can be decreased when it is combined with Loteprednol.Approved
LovastatinThe metabolism of Lacidipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Lacidipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lacidipine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineLumefantrine may increase the hypotensive activities of Lacidipine.Approved
MacitentanLacidipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineLacidipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolMannitol may increase the hypotensive activities of Lacidipine.Approved, Investigational
ME-609The serum concentration of Lacidipine can be decreased when it is combined with ME-609.Investigational
MebanazineMebanazine may increase the hypotensive activities of Lacidipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Lacidipine.Approved, Investigational
MedrysoneThe serum concentration of Lacidipine can be decreased when it is combined with Medrysone.Approved
MelengestrolThe serum concentration of Lacidipine can be decreased when it is combined with Melengestrol.Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Lacidipine.Experimental
MethazolamideMethazolamide may increase the hypotensive activities of Lacidipine.Approved
MethohexitalThe metabolism of Lacidipine can be increased when combined with Methohexital.Approved
MethoserpidineLacidipine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Lacidipine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Lacidipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Lacidipine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Lacidipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Lacidipine can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Lacidipine can be decreased when it is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMetipranolol may increase the hypotensive activities of Lacidipine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Lacidipine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
MetyrosineLacidipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Lacidipine.Experimental
MibefradilMibefradil may increase the hypotensive activities of Lacidipine.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Lacidipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Lacidipine.Approved, Investigational, Vet Approved
MidodrineMidodrine may increase the hypotensive activities of Lacidipine.Approved
MifepristoneThe serum concentration of Lacidipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineMiltefosine may increase the hypotensive activities of Lacidipine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Lacidipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Lacidipine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Lacidipine.Investigational
MitotaneThe serum concentration of Lacidipine can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Lacidipine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Lacidipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Lacidipine.Approved, Investigational
MometasoneThe serum concentration of Lacidipine can be decreased when it is combined with Mometasone.Approved, Vet Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Lacidipine.Vet Approved
MorphineMorphine may increase the hypotensive activities of Lacidipine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
MuzolimineLacidipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Lacidipine.Experimental
N,N,N-Trimethyl-2-(phosphonooxy)ethanaminiumN,N,N-Trimethyl-2-(phosphonooxy)ethanaminium may increase the hypotensive activities of Lacidipine.Experimental
NabiloneNabilone may increase the hypotensive activities of Lacidipine.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Lacidipine.Approved
NafcillinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Lacidipine.Approved
NaftopidilLacidipine may increase the hypotensive activities of Naftopidil.Investigational
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Lacidipine.Approved
NCX 1022The serum concentration of Lacidipine can be decreased when it is combined with NCX 1022.Investigational
NebivololNebivolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
NefazodoneThe serum concentration of Lacidipine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lacidipine can be increased when it is combined with Nelfinavir.Approved
NesiritideNesiritide may increase the hypotensive activities of Lacidipine.Approved, Investigational
NetupitantThe serum concentration of Lacidipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Lacidipine can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Lacidipine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Lacidipine.Approved, Investigational
NifedipineNifedipine may increase the hypotensive activities of Lacidipine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Lacidipine.Experimental
NiguldipineLacidipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Lacidipine.Investigational
NilotinibThe metabolism of Lacidipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Lacidipine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
Nitric OxideNitric Oxide may increase the hypotensive activities of Lacidipine.Approved
NitroglycerinNitroglycerin may increase the hypotensive activities of Lacidipine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Lacidipine.Approved, Investigational
Nitrous acidNitrous acid may increase the hypotensive activities of Lacidipine.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Lacidipine.Approved
NorepinephrineNorepinephrine may increase the hypotensive activities of Lacidipine.Approved
NorfenefrineNorfenefrine may increase the hypotensive activities of Lacidipine.Experimental
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Lacidipine.Approved, Vet Approved
ObinutuzumabLacidipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Lacidipine.Withdrawn
OctopamineOctopamine may increase the hypotensive activities of Lacidipine.Experimental
OlaparibThe metabolism of Lacidipine can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe serum concentration of Lacidipine can be decreased when it is combined with Oleoyl-estrone.Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Lacidipine.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Lacidipine.Experimental
OrciprenalineOrciprenaline may increase the hypotensive activities of Lacidipine.Approved
OsimertinibThe serum concentration of Lacidipine can be increased when it is combined with Osimertinib.Approved
OxethazaineOxethazaine may increase the hypotensive activities of Lacidipine.Approved, Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Lacidipine.Approved
OxilofrineOxilofrine may increase the hypotensive activities of Lacidipine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Lacidipine.Approved
OxtriphyllineOxtriphylline may increase the hypotensive activities of Lacidipine.Approved
PaclitaxelPaclitaxel may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Lacidipine.Investigational
PalbociclibThe serum concentration of Lacidipine can be increased when it is combined with Palbociclib.Approved, Investigational
PapaverinePapaverine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ParamethasoneThe serum concentration of Lacidipine can be decreased when it is combined with Paramethasone.Approved
PargylinePargyline may increase the hypotensive activities of Lacidipine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Lacidipine.Approved, Investigational
PentobarbitalThe serum concentration of Lacidipine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Lacidipine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Lacidipine.Approved, Investigational
PerifosinePerifosine may increase the hypotensive activities of Lacidipine.Investigational
PerindoprilPerindopril may increase the hypotensive activities of Lacidipine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Lacidipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Lacidipine.Withdrawn
PhenobarbitalThe serum concentration of Lacidipine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Lacidipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Lacidipine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Lacidipine.Approved
PhenylephrinePhenylephrine may increase the hypotensive activities of Lacidipine.Approved
PhenytoinThe serum concentration of Lacidipine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphorylcolaminePhosphorylcolamine may increase the hypotensive activities of Lacidipine.Experimental
PinacidilPinacidil may increase the hypotensive activities of Lacidipine.Approved
PindololPindolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
PipamperonePipamperone may increase the hypotensive activities of Lacidipine.Approved, Investigational
PirbuterolPirbuterol may increase the hypotensive activities of Lacidipine.Approved
PirlindolePirlindole may increase the hypotensive activities of Lacidipine.Approved
PitolisantThe serum concentration of Lacidipine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Lacidipine.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Lacidipine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Lacidipine.Approved
PosaconazoleThe serum concentration of Lacidipine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePramipexole may increase the hypotensive activities of Lacidipine.Approved, Investigational
PrasteroneThe serum concentration of Lacidipine can be decreased when it is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Lacidipine can be decreased when it is combined with Prasterone sulfate.Investigational
PrazosinPrazosin may increase the hypotensive activities of Lacidipine.Approved
PrednicarbateThe serum concentration of Lacidipine can be decreased when it is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe serum concentration of Lacidipine can be decreased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Lacidipine can be decreased when it is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe serum concentration of Lacidipine can be decreased when it is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe serum concentration of Lacidipine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ProcaterolProcaterol may increase the hypotensive activities of Lacidipine.Approved, Investigational
PropofolPropofol may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
PropranololLacidipine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolProtokylol may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Lacidipine.Experimental
QuetiapineQuetiapine may increase the hypotensive activities of Lacidipine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Lacidipine.Approved
RacepinephrineRacepinephrine may increase the hypotensive activities of Lacidipine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Lacidipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Lacidipine.Approved
RanolazineThe metabolism of Lacidipine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Lacidipine.Approved
RemifentanilRemifentanil may increase the hypotensive activities of Lacidipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Lacidipine.Approved
ReproterolReproterol may increase the hypotensive activities of Lacidipine.Investigational
RescinnamineLacidipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Lacidipine.Approved, Investigational
RifabutinThe serum concentration of Lacidipine can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Lacidipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Lacidipine can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Lacidipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
RimexoloneThe serum concentration of Lacidipine can be decreased when it is combined with Rimexolone.Approved
RiociguatRiociguat may increase the hypotensive activities of Lacidipine.Approved
RisperidoneLacidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabLacidipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleRopinirole may increase the hypotensive activities of Lacidipine.Approved, Investigational
RopivacaineRopivacaine may increase the hypotensive activities of Lacidipine.Approved
RotigotineRotigotine may increase the hypotensive activities of Lacidipine.Approved
RucaparibThe metabolism of Lacidipine can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilSacubitril may increase the hypotensive activities of Lacidipine.Approved
SafrazineSafrazine may increase the hypotensive activities of Lacidipine.Withdrawn
SalbutamolSalbutamol may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Lacidipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Lacidipine.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the hypotensive activities of Lacidipine.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Lacidipine.Experimental
SaquinavirThe serum concentration of Lacidipine can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Lacidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
SelexipagLacidipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Lacidipine.Approved, Investigational
SevofluraneSevoflurane may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Lacidipine.Approved
SiltuximabThe serum concentration of Lacidipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Lacidipine can be increased when it is combined with Simeprevir.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Lacidipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Lacidipine.Approved, Investigational
SitaxentanLacidipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolSotalol may increase the hypotensive activities of Lacidipine.Approved
SpiraprilSpirapril may increase the hypotensive activities of Lacidipine.Approved
SpironolactoneSpironolactone may increase the hypotensive activities of Lacidipine.Approved
St. John's WortThe serum concentration of Lacidipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Lacidipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the hypotensive activities of Lacidipine.Approved, Investigational
SuccinylcholineSuccinylcholine may increase the hypotensive activities of Lacidipine.Approved
SufentanilSufentanil may increase the hypotensive activities of Lacidipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Lacidipine.Approved
SulfisoxazoleThe metabolism of Lacidipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SynephrineSynephrine may increase the hypotensive activities of Lacidipine.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
TalinololLacidipine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Lacidipine.Approved, Investigational
TelaprevirThe serum concentration of Lacidipine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Lacidipine can be increased when it is combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Lacidipine.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Lacidipine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Lacidipine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the hypotensive activities of Lacidipine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Lacidipine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Lacidipine.Approved, Investigational
TetrahydropalmatineLacidipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThalidomide may increase the hypotensive activities of Lacidipine.Approved, Investigational, Withdrawn
TheodrenalineTheodrenaline may increase the hypotensive activities of Lacidipine.Investigational
ThiamylalThe metabolism of Lacidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Lacidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Lacidipine.Approved
TiboloneTibolone may increase the hypotensive activities of Lacidipine.Approved, Investigational
TiclopidineThe metabolism of Lacidipine can be decreased when combined with Ticlopidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Lacidipine.Withdrawn
TimololTimolol may increase the hypotensive activities of Lacidipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Lacidipine.Approved
TixocortolThe serum concentration of Lacidipine can be decreased when it is combined with Tixocortol.Approved, Withdrawn
TizanidineTizanidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
TocilizumabThe serum concentration of Lacidipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
TolcaponeTolcapone may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Lacidipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Lacidipine.Approved, Investigational, Vet Approved
TolonidineLacidipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Lacidipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Lacidipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Lacidipine.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Lacidipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Lacidipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Lacidipine.Approved, Investigational
TretinoinTretinoin may increase the hypotensive activities of Lacidipine.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Lacidipine can be decreased when it is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTriamterene may increase the hypotensive activities of Lacidipine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
TrifluoroethanolTrifluoroethanol may increase the hypotensive activities of Lacidipine.Experimental
TrimazosinTrimazosin may increase the hypotensive activities of Lacidipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Lacidipine.Approved, Investigational
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Lacidipine.Approved, Investigational
TrolamineTrolamine may increase the hypotensive activities of Lacidipine.Approved, Experimental
TrolnitrateTrolnitrate may increase the hypotensive activities of Lacidipine.Experimental
TulobuterolTulobuterol may increase the hypotensive activities of Lacidipine.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
UlobetasolThe serum concentration of Lacidipine can be decreased when it is combined with Ulobetasol.Approved
UnoprostoneUnoprostone may increase the hypotensive activities of Lacidipine.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Lacidipine.Investigational
ValsartanValsartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Lacidipine.Approved
VemurafenibThe serum concentration of Lacidipine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Lacidipine can be decreased when combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Lacidipine.Approved
ViminolViminol may increase the hypotensive activities of Lacidipine.Experimental
VincamineLacidipine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineLacidipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Lacidipine can be increased when it is combined with Voriconazole.Approved, Investigational
XipamideLacidipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Lacidipine.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Lacidipine.Approved, Investigational, Vet Approved
ZiprasidoneThe metabolism of Lacidipine can be decreased when combined with Ziprasidone.Approved
ZofenoprilLacidipine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Lacidipine synthesis: C. Semeraro et al., DE 3529997; eidem, U.S. Patent 4,801,599 (1986, 1989 both to Glaxo).

General References
  1. McCormack PL, Wagstaff AJ: Lacidipine: a review of its use in the management of hypertension. Drugs. 2003;63(21):2327-56. [PubMed:14524737]
  2. Lee CR, Bryson HM: Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs. 1994 Aug;48(2):274-96. [PubMed:7527328]
  3. Herbette LG, Gaviraghi G, Tulenko T, Mason RP: Molecular interaction between lacidipine and biological membranes. J Hypertens Suppl. 1993 Mar;11(1):S13-9. [PubMed:8387105]
  4. Ishii N, Matsumura T, Shimoda S, Araki E: Anti-atherosclerotic potential of dihydropyridine calcium channel blockers. J Atheroscler Thromb. 2012;19(8):693-704. Epub 2012 May 17. [PubMed:22653165]
  5. Cerbai E, Giotti A, Mugelli A: Characteristics of L-type calcium channel blockade by lacidipine in guinea-pig ventricular myocytes. Br J Pharmacol. 1997 Feb;120(4):667-75. doi: 10.1038/sj.bjp.0700951. [PubMed:9051306]
  6. Lacidipine Summary of Product Characteristics [Link]
External Links
KEGG Drug
D04657
PubChem Compound
5311217
PubChem Substance
310265140
ChemSpider
4470736
ChEBI
135737
ChEMBL
CHEMBL460291
Wikipedia
Lacidipine
ATC Codes
C08CA09 — Lacidipine
MSDS
Download (78.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers4
2CompletedTreatmentAngina Pectoris1
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4CompletedTreatmentHypertension,Essential / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableTerminatedNot AvailableHigh Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00224 mg/mLALOGPS
logP5.18ALOGPS
logP4.19ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)19.47ChemAxon
pKa (Strongest Basic)-6.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area90.93 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity129.91 m3·mol-1ChemAxon
Polarizability49.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00fr-0000900000-2964b6b69c71aeda6088
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0169400000-672099fb92e2023950eb

Taxonomy

Description
This compound belongs to the class of organic compounds known as cinnamic acid esters. These are compound containing an ester derivative of cinnamic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Cinnamic acid esters
Direct Parent
Cinnamic acid esters
Alternative Parents
Tricarboxylic acids and derivatives / Dihydropyridinecarboxylic acids and derivatives / Styrenes / Fatty acid esters / Vinylogous amides / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines / Azacyclic compounds
show 4 more
Substituents
Cinnamic acid ester / Dihydropyridinecarboxylic acid derivative / Tricarboxylic acid or derivatives / Styrene / Dihydropyridine / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Hydropyridine / Benzenoid
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...

Components:
References
  1. Cerbai E, Giotti A, Mugelli A: Characteristics of L-type calcium channel blockade by lacidipine in guinea-pig ventricular myocytes. Br J Pharmacol. 1997 Feb;120(4):667-75. doi: 10.1038/sj.bjp.0700951. [PubMed:9051306]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lacidipine Summary of Product Characteristics [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lacidipine Summary of Product Characteristics [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Lacidipine Summary of Product Characteristics [Link]

Drug created on October 23, 2015 10:33 / Updated on March 02, 2018 03:48